News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
345,896 Results
Type
Article (21109)
Company Profile (141)
Press Release (324632)
Multimedia
Podcasts (112)
Webinars (17)
Section
Business (105945)
Career Advice (891)
Deals (18670)
Drug Delivery (110)
Drug Development (51075)
Employer Resources (80)
FDA (7854)
Job Trends (7825)
News (187008)
Policy (17480)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (739)
Accelerated approval (19)
Adcomms (23)
Allergies (84)
Alliances (27986)
ALS (90)
Alzheimer's disease (791)
Antibody-drug conjugate (ADC) (207)
Approvals (8031)
Artificial intelligence (283)
Autoimmune disease (83)
Automation (15)
Bankruptcy (178)
Best Places to Work (5554)
BIOSECURE Act (14)
Biosimilars (170)
Biotechnology (60)
Bladder cancer (75)
Brain cancer (34)
Breast cancer (265)
Cancer (2315)
Cardiovascular disease (240)
Career advice (740)
Career pathing (24)
CAR-T (111)
CDC (14)
Cell therapy (289)
Cervical cancer (11)
Clinical research (44834)
Collaboration (1018)
Company closure (1)
Compensation (372)
Complete response letters (52)
COVID-19 (1156)
CRISPR (49)
C-suite (541)
Cystic fibrosis (88)
Data (3307)
Decentralized trials (2)
Denatured (27)
Depression (84)
Diabetes (249)
Diagnostics (1893)
Digital health (15)
Diversity (9)
Diversity, equity & inclusion (22)
Drug discovery (174)
Drug pricing (200)
Drug shortages (33)
Duchenne muscular dystrophy (138)
Earnings (40915)
Editorial (46)
Employer branding (10)
Employer resources (79)
Events (50949)
Executive appointments (623)
FDA (9434)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (658)
Gene editing (90)
Generative AI (31)
Gene therapy (269)
GLP-1 (827)
Government (2020)
Grass and pollen (4)
Guidances (205)
Healthcare (5924)
HIV (29)
Huntington's disease (24)
IgA nephropathy (60)
Immunology and inflammation (169)
Immuno-oncology (36)
Indications (68)
Infectious disease (1289)
Inflammatory bowel disease (119)
Inflation Reduction Act (12)
Influenza (46)
Intellectual property (136)
Interviews (118)
IPO (7430)
IRA (53)
Job creations (2442)
Job search strategy (653)
JPM (52)
Kidney cancer (10)
Labor market (61)
Layoffs (343)
Leadership (27)
Legal (4156)
Liver cancer (37)
Longevity (8)
Lung cancer (336)
Lymphoma (208)
Machine learning (21)
Management (31)
Manufacturing (529)
MASH (104)
Medical device (2005)
Medtech (2013)
Mergers & acquisitions (11771)
Metabolic disorders (889)
Multiple sclerosis (103)
NASH (20)
Neurodegenerative disease (161)
Neuropsychiatric disorders (71)
Neuroscience (1521)
Neurotech (1)
NextGen: Class of 2026 (2363)
Non-profit (918)
Now hiring (45)
Obesity (521)
Opinion (232)
Ovarian cancer (66)
Pain (147)
Pancreatic cancer (95)
Parkinson's disease (155)
Partnered (18)
Patents (279)
Patient recruitment (245)
Peanut (19)
People (34491)
Pharmaceutical (76)
Pharmacy benefit managers (33)
Phase 1 (14125)
Phase 2 (18914)
Phase 3 (15200)
Pipeline (2916)
Policy (235)
Postmarket research (1619)
Preclinical (4940)
Press Release (29)
Prostate cancer (132)
Psychedelics (27)
Radiopharmaceuticals (182)
Rare diseases (525)
Real estate (3206)
Recruiting (34)
Regulatory (13774)
Reports (25)
Research institute (837)
Resumes & cover letters (140)
Rett syndrome (6)
RNA editing (12)
RSV (43)
Schizophrenia (118)
Series A (119)
Series B (88)
Service/supplier (7)
Sickle cell disease (65)
Special edition (21)
Spinal muscular atrophy (119)
Sponsored (18)
Startups (2041)
State (2)
Stomach cancer (12)
Supply chain (76)
Tariffs (94)
The Weekly (83)
Vaccines (406)
Venture capital (68)
Weight loss (380)
Women's health (41)
Worklife (9)
Date
Today (70)
Last 7 days (293)
Last 30 days (1109)
Last 365 days (15294)
2026 (1570)
2025 (15485)
2024 (17672)
2023 (19639)
2022 (25875)
2021 (26643)
2020 (24876)
2019 (20063)
2018 (15594)
2017 (17258)
2016 (16208)
2015 (18804)
2014 (14793)
2013 (12556)
2012 (13486)
2011 (13823)
2010 (12739)
Location
Africa (414)
Alabama (41)
Alaska (1)
Arizona (92)
Arkansas (8)
Asia (25999)
Australia (3333)
California (4802)
Canada (1825)
China (756)
Colorado (197)
Connecticut (195)
Delaware (181)
Europe (53513)
Florida (836)
Georgia (97)
Hawaii (2)
Idaho (18)
Illinois (442)
India (53)
Indiana (294)
Iowa (5)
Japan (323)
Kansas (83)
Kentucky (29)
Louisiana (7)
Maine (4)
Maryland (597)
Massachusetts (3867)
Michigan (68)
Minnesota (241)
Mississippi (3)
Missouri (42)
Montana (12)
Nebraska (14)
Nevada (35)
New Hampshire (10)
New Jersey (1858)
New Mexico (21)
New York (1315)
North Carolina (799)
North Dakota (2)
Northern California (2248)
Ohio (130)
Oklahoma (8)
Oregon (23)
Pennsylvania (1063)
Puerto Rico (20)
Rhode Island (27)
South America (616)
South Carolina (11)
Southern California (2035)
Tennessee (64)
Texas (653)
United States (18203)
Utah (95)
Virginia (178)
Washington D.C. (60)
Washington State (375)
West Virginia (1)
Wisconsin (50)
Wyoming (1)
345,896 Results for "sichuan kelun pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
The partnership will focus on Crescent’s PD-1/VEGF inhibitor CR-001 and Kelun-Biotech’s SKB105, both of which the companies plan to push into Phase I/II development for solid tumors early next year.
December 4, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
February 6, 2026
·
6 min read
Press Releases
Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference
January 16, 2026
·
5 min read
Press Releases
Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference, Sharing Its Business Progresses and Innovation Strategies
January 7, 2026
·
2 min read
Press Releases
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
January 5, 2026
·
3 min read
Press Releases
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
December 4, 2025
·
11 min read
Press Releases
Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
January 5, 2026
·
5 min read
Press Releases
KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS
August 18, 2025
·
14 min read
Press Releases
Kelun-Biotech’s Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC
October 17, 2025
·
4 min read
Press Releases
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
November 10, 2025
·
8 min read
1 of 34,590
Next
